Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-02-23 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2011
Regulatory Filings Classification · 100% confidence The document is a letter from Novartis AG to the SEC requesting acceleration of effectiveness of a Registration Statement on Form F-4 under the Securities Act of 1933. It is a formal communication related to a regulatory filing process, specifically concerning the timing of the effectiveness of a registration statement. The document does not contain financial statements, management discussion, or detailed report content. It is primarily a regulatory correspondence and certification related to a filing process. The document length is short (2862 characters), and it is clearly a letter requesting an administrative action rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory communications that do not fit other specific categories.
2011-02-23 English
6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes an investor relations release about the Annual General Meeting (AGM) results, including shareholder approval of dividend increases, election and re-election of board members, and reaffirmation of the group outlook. It also discusses corporate governance and compensation system votes. The document is not the full annual report or financial statements but rather an announcement of AGM outcomes and related shareholder resolutions. The length is about 13,873 characters, which is substantial but the content is focused on shareholder meeting results and dividend announcements rather than detailed financial data or management discussion. Therefore, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2011-02-23 English
SC TO-T/A Filing
M&A Activity Classification · 100% confidence The document is titled 'Amendment No. 2 to Tender Offer Statement on Schedule TO' and references the Securities Exchange Act of 1934. It involves a tender offer by Novartis AG and its subsidiaries to purchase shares of Genoptix, Inc. The text includes details about the offer price, transaction valuation, and legal settlements related to the tender offer. The Schedule TO is a specific SEC filing used for tender offers. The document is an amendment to a Schedule TO filing, which is related to takeover bids and tender offers. This matches the definition of 'M&A Activity' filings, which include announcements and documents related to merger proposals or takeover bids. The document is not a full annual or interim report, nor is it a simple announcement or certification. Therefore, the correct classification is 'TAR' for M&A Activity.
2011-02-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing a positive opinion from the European Medicines Agency's CHMP for a new drug combination (Rasilamlo) to treat high blood pressure. The document contains detailed information about the drug, clinical trial data, and forward-looking statements, but it does not contain financial statements or comprehensive financial performance data. It is not an annual or interim report, nor is it an earnings release or management discussion. It is a regulatory announcement of a corporate development related to product approval and clinical data. The document length is about 13,963 characters, which is substantial, but the content is primarily a press release rather than a financial report. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2011-02-18 English
6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content primarily announces the appointment of a new head for the Novartis OTC division and organizational changes within the company. It includes forward-looking statements and disclaimers but does not contain financial statements, detailed financial analysis, or audit information. The document is about management changes and organizational restructuring rather than a full annual or interim report, audit report, or earnings release. It is not a call transcript, capital update, or legal proceeding report. Given the focus on appointment and organizational structure changes at the executive level, the document fits best under Board/Management Information (MANG). The document length is 9479 characters, which is substantial but the content is clearly an announcement of management appointment and division restructuring. Therefore, the classification is MANG with high confidence.
2011-02-18 English
AMENDMENT NO. 2 TO SCHEDULE 13E-3
M&A Activity Classification · 95% confidence The document is an Amendment No. 2 to Schedule 13E-3 filed with the SEC, which is a Rule 13e-3 Transaction Statement under Section 13(e) of the Securities Exchange Act of 1934. It relates to a merger transaction between Novartis AG and Alcon, Inc. The document includes detailed information about the merger terms, background, fairness, and related agreements. Schedule 13E-3 filings are specifically used for transactions involving mergers or going-private transactions and are regulatory filings related to M&A activity. The document is not a full merger proxy statement (which would be Form DEFM14A) but a transaction statement under Rule 13e-3. Given the detailed nature and regulatory context, this filing is best classified under M&A Activity (TAR) as it pertains to merger-related disclosures and transaction statements. The document is lengthy (15,000 characters) and contains substantive information about the transaction, not merely an announcement or a certification, so it is not RNS or RPA. Therefore, the most appropriate classification is TAR with high confidence.
2011-02-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.